 |
 |
 | Webcast - Live
Synta Pharmaceuticals Corp. at Robert W. Baird & Co., Inc. Health Care Conference
09/14/10 at 3:45 p.m. ET |
| Webcast - Replay
Synta Pharmaceuticals Corp. at Canaccord Genuity 30th Annual Growth Conference
08/12/10 at 1:30 p.m. ET |
 |
|
|
| Date | Title | | | 09/08/10 | Synta Pharmaceuticals to Present at the Robert W. Baird 2010 Health Care Conference|
Company to Webcast Presentation on September 14
LEXINGTON, Mass., Sep 8, 2010 (BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA - News), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Company will be presenting at the Robert W. Baird 2010 Health Care Conference on Tuesday, September 14 at 3:45 p.m. (ET) in New York.
A live audio webcast and replay of the presenta... |
|  | | 08/24/10 | Synta Announces First Patient Treated in Clinical Trial of STA-9090 in Combination with Docetaxel in Solid Tumors| First combination trial of potent second-generation Hsp90 inhibitor
LEXINGTON, Mass., Aug 24, 2010 (BUSINESS WIRE) -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the first patient has been treated in its clinical trial of STA-9090 in combination with docetaxel for the treatment of advanced solid tumor malignancies. This is the first ... |
| | | 08/09/10 | Synta Pharmaceuticals Reports Second-Quarter 2010 Financial Results and Clinical Update| - STA-9090 Phase 2 trials in hepatic and small cell lung cancer initiated -
- First STA-9090 combination trial initiated -
- Additional evidence supportive of predictive role for LDH in elesclomol activity shown -
LEXINGTON, Mass., Aug 09, 2010 (BUSINESS WIRE) -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quart... |
| | | 08/05/10 | Synta Pharmaceuticals to Present at the Canaccord Genuity Annual Growth Conference| Company to Webcast Presentation on August 12
LEXINGTON, Mass., Aug 05, 2010 (BUSINESS WIRE) -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Company will be presenting at the Canaccord Genuity 30th Annual Growth Conference on Thursday, August 12 at 1:30 p.m. (ET) in Boston.
A live audio webcast and replay of the presentation wi... |
| | | 07/27/10 | Synta Announces STA-9090 Results Published in Journal "Blood" Demonstrating Potent In Vitro and In Vivo Activity in AML| - STA-9090 inhibits WT1, a key driver of leukemias -
- STA-9090 enhances activity of chemotherapy in leukemia cells -
- STA-9090 currently being studied in two AML clinical trials -
LEXINGTON, Mass., Jul 27, 2010 (BUSINESS WIRE) -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that results pre-published in the online edition of the journal Blood show that STA-9090 causes degradation of the Wilms' tumor 1 (WT1) protein and its downstream target proteins, c-Myc and Bcl-2, key fac... |
| | | 07/26/10 | Synta Pharmaceuticals to Host Second-Quarter 2010
Conference Call on August 9, 2010|
Conference call to be held after market closes
LEXINGTON, Mass., Jul 26, 2010 (BUSINESS WIRE) -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it will release its second-quarter 2010 financial results after the market closes on Monday, August 9, 2010.
Management will conduct a conference call at 4:30 p.m. (ET) that day to revie... |
| | | 06/07/10 | Synta Announces Encouraging STA-9090 Clinical Results Presented at ASCO| - STA-9090 well-tolerated in Phase 1 solid tumor studies at dose levels up to 216mg/m2 -
- Promising single-agent clinical activity observed across multiple tumor types -
LEXINGTON, Mass., Jun 07, 2010 (BUSINESS WIRE) --Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced that clinical results for two Phase 1 trials of STA-9090 in solid tumors, as well as 12 month updated survival results from the SYMMETRY trial of elesclomol in metastatic melanoma, were presented at the 2010 Annual Meeting ... |
| | | 06/03/10 | Synta Pharmaceuticals to Present at the Jefferies Global Life
Sciences Conference| Company to Webcast Presentation on June 10
LEXINGTON, Mass., Jun 03, 2010 (BUSINESS WIRE) --Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company
focused on discovering, developing, and commercializing small molecule
drugs to treat severe medical conditions, today announced that the
Company will be presenting at the Jefferies Global Life Sciences
Conference on Thursday, June 10 at 3:30 p.m. (ET) in New York.
A live audio webcast and replay ... |
| | | 05/24/10 | Synta Announces Clinical Data Presentations at ASCO| LEXINGTON, Mass., May 24, 2010 (BUSINESS WIRE) --Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that results
from a Phase 1 study of STA-9090, a potent, second-generation Hsp90
inhibitor, will be the subject of a poster discussion session in the
Developmental Therapeutics session at the American Society for Clinical
Oncology (ASCO) Annual Meeting 2010 on Saturday, June 5 at 12:30 p.m.
STA-9090 Posters and Poster Discussions
"A Phase 1 dose-escalati... |
| | | 05/24/10 | Synta Announces Positive Results in Phase 2 NSCLC Trial for STA-9090
Support Advancing Trial to Second Stage| - Pre-Specified Efficacy Criteria Achieved in Lung Cancer Trial -
LEXINGTON, Mass., May 24, 2010 (BUSINESS WIRE) --Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that clinical
activity seen in the first stage of its trial for STA-9090 in Stage IIIB
and Stage IV patients with non-small cell lung cancer (NSCLC), support
advancing to the second stage of the trial. This result was achieved in
the first pre-defined patient cohort to complete enrollment. ... |
| | | 05/04/10 | Synta Pharmaceuticals Reports First Quarter 2010 Financial Results| Phase 2 trials initiated for STA-9090 in colon and gastric cancers
LEXINGTON, Mass., May 04, 2010 (BUSINESS WIRE) --Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended March 31, 2010.
"Synta has made significant progress this year in advancing our lead oncology programs, as well as strengthening our financ... |
| | | 04/22/10 | Synta Pharmaceuticals to Host First-Quarter 2010
Conference Call on May 4, 2010| LEXINGTON, Mass., Apr 22, 2010 (BUSINESS WIRE) --Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it will release its first-quarter 2010 financial results before the market opens on Tuesday, May 4, 2010.
Management will conduct a conference call at 10:00 a.m. (ET) that morning to review the Company's first-quarter financial results. The co... |
| | | 04/20/10 | Synta Presents Results at AACR Supporting Correlative Markers for Elesclomol Activity| - Link demonstrated between elesclomol anti-cancer activity and levels of HIF-1a and LDH -
- Additional results presented demonstrating activity of elesclomol in cisplatin-resistant lung cancer models -
LEXINGTON, Mass., Apr 20, 2010 (BUSINESS WIRE) --Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced preclinical results presented at the Americ... |
| | | 04/19/10 | Synta Presents STA-9090 Results at AACR Including Synergy with Avastin(R), Tarceva(R), and Taxanes; Downregulation of HIF-1a; Inhibition of JAK/STAT| - STA-9090 shows in vitro and in vivo synergy with standard of care lung cancer agents -
- STA-9090 penetrates hypoxic regions of tumors and inhibits HIF-1a expression -
- STA-9090 inhibits JAK/STAT pathway, linked to cancer cell growth -
LEXINGTON, Mass., Apr 19, 2010 (BUSINESS WIRE) --Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced th... |
| | | 04/07/10 | Synta Announces Poster Presentations at the American Association for Cancer Research Annual Meeting| LEXINGTON, Mass., Apr 07, 2010 (BUSINESS WIRE) --Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Synta will present multiple posters at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 to be held April 17-21, 2010 in Washington, DC. The presentations will include three posters on STA-9090, a potent inhibitor of ... |
| | | 03/16/10 | Synta Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference| Company to Webcast Presentation on March 24
LEXINGTON, Mass., Mar 16, 2010 (BUSINESS WIRE) -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Company will be presenting at the Barclays Capital 2010 Global Healthcare Conference on Wednesday, March 24 at 9:00 a.m. (ET) in Miami, Florida.
A live audio webcast and replay of the presentat... |
| | | 03/11/10 | Synta Pharmaceuticals Reports Fourth Quarter
and Full Year 2009 Financial Results| LEXINGTON, Mass., Mar 11, 2010 (BUSINESS WIRE) -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported fourth-quarter and full-year 2009 financial results, provided an update on recent progress with its programs, and announced 2010 objectives.
"We have made significant recent progress with STA-9090, elesclomol, and our CRACM ion channel program," sa... |
| | | 03/10/10 | Synta Pharmaceuticals to Present at the Roth Capital Partners 22nd Annual OC Growth Stock Conference| Company to Webcast Presentation on March 17
LEXINGTON, Mass., Mar 10, 2010 (BUSINESS WIRE) -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Company will be presenting at the Roth Capital OC Growth Stock Conference on Wednesday, March 17 at 8:00 a.m. (PST) in Laguna Niguel, California.
A live audio webcast and replay of the presenta... |
| | | 03/02/10 | Synta Announces Elesclomol Clinical Development to Resume| LEXINGTON, Mass., Mar 02, 2010 (BUSINESS WIRE) -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported that the U.S. Food and Drug Administration (FDA) has approved resuming clinical development of elesclomol, the Company's first-in-class oxidative stress inducer.
"The collected clinical and preclinical data presented to the FDA and to our external ... |
| | | 02/26/10 | Synta Presents STA-9090 NSCLC data at the IASLC
10th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting|
-STA-9090 shows activity against EGFR T790M resistance mutation -
- Simultaneously inhibits MET, a key mechanism of resistance, and EGFR -
LEXINGTON, Mass., Feb 26, 2010 (BUSINESS WIRE) -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Geoffrey I. Shapiro of Dana-Farber Cancer Institute, presented preclinical and clinical data on... |
| | | 02/25/10 | Synta Pharmaceuticals to Host Fourth-Quarter and Year-End 2009 Conference Call on March 11, 2010| LEXINGTON, Mass., Feb 25, 2010 (BUSINESS WIRE) -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it will release its fourth-quarter and year-end 2009 financial results before the market opens on Thursday, March 11, 2010.
Management will conduct a conference call at 10:00 a.m. (ET) that morning to review the Company's fourth-quarter and y... |
| | | 02/23/10 | Synta Pharmaceuticals to Participate in Panel Titled New Targets in Cancer Therapy at the RBC Capital Markets Healthcare Conference| Company to Webcast Panel Presentation on March 2LEXINGTON, Mass., Feb 23, 2010 (BUSINESS WIRE) -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that President and CEO Safi Bahcall, Ph.D., will participate in a panel discussion titled New Targets in Cancer Therapy at the RBC Capital Markets Healthcare Conference on Tuesday, March 2 at 8:00 am (... |
| | | 02/08/10 | Synta Announces STA-9090 Results
Demonstrating Potent in vitro and in vivo Activity in AML|
- Results presented at hematologic malignancies conference in Singapore -
- STA-9090 inhibits WT1, a key driver of leukemias -
- STA-9090 currently being studied in two AML clinical trials -LEXINGTON, Mass., Feb 08, 2010 (BUSINESS WIRE) -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that preclinical results presented at the "Bridging the Gap 2010" Hematologic Conference, held in Singapore City, Singapore, February 5-7, 2010, shows that STA-9090, a potent inhibitor of heat shoc... |
| | | 02/01/10 | Synta Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference| Company to Webcast Presentation on February 8LEXINGTON, Mass., Feb 01, 2010 (BUSINESS WIRE) -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company will be presenting at the 2010 BIO CEO & Investor Conference on Monday, February 8 at 8:30 am (ET) at the Waldorf Astoria Hotel in New York.
A live audio webcast and replay of the panel will be available on the "Investors" section of the Company's website, http://www.syntapharma.com.
About Synta Pharmaceuticals
Synta Pharm... |
| | | 01/19/10 | Synta Pharmaceuticals Sells Additional $3.75 Million of Common Stock| LEXINGTON, Mass., Jan 19, 2010 (BUSINESS WIRE) -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced the completion of the sale of 833,333 additional shares of its common stock pursuant to the full exercise of the over-allotment option granted to the underwriters of its previously announced public offering. The shares were sold at a price to the pu... |
| | | 01/12/10 | Synta Presents Results at AACR-IASLC Demonstrating Potent and
Synergistic Activity of STA-9090 in NSCLC Cell Lines Including Mutated
EGFR, HER2, and KRAS| LEXINGTON, Mass., Jan 12, 2010 (BUSINESS WIRE) -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company
focused on discovering, developing, and commercializing small molecule
drugs to treat severe medical conditions, today announced that
preclinical results presented at the AACR-IASLC (American Academy of
Cancer Research - International Association for the Study of Lung
Cancer) Joint Conference based on work done at Synta and at the
... |
| | | 01/08/10 | Synta Pharmaceuticals Prices $25 Million Public Offering of Common
Stock| LEXINGTON, Mass., Jan 08, 2010 (BUSINESS WIRE) -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company
focused on discovering, developing, and commercializing small molecule
drugs to treat severe medical conditions, today announced the pricing of
an underwritten public offering of 5,555,556 shares of its common stock
at a price to the public of $4.50 per share for gross proceeds of
approximately $25 million. After underwriting discounts ... |
| | | 01/07/10 | Synta Pharmaceuticals Announces Proposed Public Offering of Common Stock| LEXINGTON, Mass., Jan 07, 2010 (BUSINESS WIRE) -- Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it intends to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of commo... |
| |
|
| |
